Oncologists Risk Self-Referral Violations Over Medicare Mail-Order Drug Rule
A new interpretation of a decades-old law could put community oncology practices in the crosshairs of regulators who monitor and enforce provisions against self-referral and add a barrier to patient access. Enacted by Congress in 1989, the Medicare Physician Self-Referral Law, commonly called the Stark law, prohibits physicians from referring patients to receive services from […]
Opinion | Transitioning Cancer Survivors Away From Oncologic Care
Dinan is an associate professor of epidemiology and an oncology outcomes researcher. October was Breast Cancer Awareness month and the sudden influx of pink in our homes, on our televisions, in our workplaces, and in local businesses reminded us that we still lose far too many of our loved ones to cancer, not only in […]
My Son’s Brain Tumor Was Benign. We Thought We Were In The Clear — But We Were Wrong.
The author’s son consulting with his doctor, Eugene Hwang, associate chief of oncology at Children’s National Hospital in Washington, during treatment in 2020. Courtesy of Adina Ciment I saw the mass on my son’s brain from the small booth in the CT room. It didn’t take much to realize that the golf-ball-sized circle on one […]
Testing PD-1 Inhibition With Neoadjuvant Anti-HER2 Therapy in Breast Cancer
At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported on a multicenter, phase II trial exploring the efficacy and safety of adding pembrolizumab (Keytruda) to the standard-of-care treatment of paclitaxel (Taxol), trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) in chemotherapy-naive patients with invasive, HER2-positive breast cancer. In this exclusive MedPage Today video, Jin […]
PD-1 Inhibition in First-Line Prolongs Survival in Cervical Cancer
Updated findings of KEYNOTE-826, presented at the American Society of Clinical Oncology (ASCO) annual meeting, continued to demonstrate a significant survival benefit with the addition of pembrolizumab (Keytruda) to standard treatment for previously untreated recurrent or metastatic cervical cancer. In this exclusive MedPage Today video, Deanna Gerber, MD, of the NYU Long Island School of […]
Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancer
Clovis Oncology has voluntarily withdrawn the indication for rucaparib (Rubraca) as a third-line treatment in BRCA-mutated ovarian cancer after an overall survival (OS) analysis showed a signal for potential harm, according to a filing with the Securities and Exchange Commission (SEC). “Based on further discussions with the FDA following submission of ARIEL4 OS data previously […]